Cogstate Limited (ASX:CGS): What Does the FY27 Contract Backlog Reveal After Its Latest Trial Wins?

Aditi Sarkar

27 October 2026 10:33 PM AEDT

Cogstate Limited (ASX:CGS): What Does the FY27 Contract Backlog Reveal After Its Latest Trial Wins?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cogstate Limited (ASX:CGS) signed USD 25.13mn in net sales contracts during 1Q FY27.
Total contracted revenue reached USD 143.7mn at 30 September 2026, up 41% YoY.
FY26 revenue rose approximately 15% YoY to USD 60.86mn, with net profit of USD 11.9mn.
Contracted FY27 revenue stood at USD 56.8mn, compared with USD 39.2mn a year earlier.

Cogstate Limited develops digital cognitive assessments and provides clinical-trial endpoint quality services to pharmaceutical and biotechnology customers studying central nervous system disorders. After reporting new late-stage trial contracts and an expanded revenue backlog in October, Cogstate Limited (ASX:CGS) shares closed at AUD 3.42 on 27 October 2026. Its latest quarterly business update follows higher FY26 revenue and profit and highlights the timing gap between contract wins and the recognition of revenue across lengthy clinical studies.

Company Business

Cogstate Limited (ASX:CGS) supplies cognitive-testing technology, scientific services and data quality programs used to assess treatment effects in clinical research. Its Clinical Trials business supports sponsors running neurological, psychiatric and other central nervous system studies, including trials that require consistent administration and scoring of cognitive assessments across multiple sites and languages.

The Healthcare business seeks to make brief, validated digital cognitive assessments available for use by healthcare professionals and patients. Cogstate also offers analytics and endpoint measurement expertise alongside its software. Clinical-trial contracts are generally delivered over several reporting periods, and their duration varies considerably by development phase. This means commercial bookings and accounting revenue are not interchangeable measures.

Recent Development

In its October 2026 update for the September quarter, Cogstate Limited (ASX:CGS) reported net sales contracts of USD 25.13mn, compared with USD 21.42mn in the corresponding quarter of FY26, an increase of approximately 17% YoY. The company attributed more than 80% of quarterly contract value to five Phase 3 trial wins across two customers in bipolar disorder or depression. The proportion tied to a small number of studies illustrates the effect that individual contracts can have on quarterly bookings.

At 30 September 2026, total contracted revenue, including amounts already recognised in 1Q FY27, was USD 143.7mn, against USD 101.8mn one year earlier. Contracted revenue attributable to FY27 rose to USD 56.8mn from USD 39.2mn, while contracted revenue relating to FY28-FY33 reached USD 86.9mn, compared with USD 62.6mn. The company noted that longer Phase 3 studies tend to spread revenue over several years.

The latest quarter also included USD 8.4mn of new contracts allocated to FY27, equivalent to a 34% in-year revenue yield. Cogstate explained that the yield reflected licence fees contributing only 7% of quarterly sales, below its historical 20%-25% range, as well as the unusually high share of longer-duration trials.

Financial Performance and Sector Context

For the year ended 30 June 2026, Cogstate Limited (ASX:CGS) reported group revenue of approximately USD 60.86mn, up 14.6% from USD 53.09mn in FY25. Net profit after tax was approximately USD 11.9mn, versus USD 10.14mn, an increase of about 17%. The company also reported USD 89.0mn of new FY26 sales contracts, compared with USD 41.26mn a year earlier, reflecting an increase in the value of newly signed work.

At the FY26 year-end, Cogstate reported approximately USD 34.8mn in cash and no debt. Its board declared an annual fully franked dividend of AUD 0.04 per share. The group entered FY27 with USD 118.5mn in contracted future revenue, including USD 48.3mn then allocated to FY27. The subsequent September update increased the FY27 contracted amount to USD 56.8mn, which provides a more recent indication of booked work rather than a guarantee of realised sales.

Demand for specialist CNS assessments depends on trial funding, sponsors’ research priorities, recruitment schedules and the progression of drug programs. The mix between shorter studies and multiyear Phase 3 trials also influences when contracted amounts become recognised revenue. International operations create exposure to foreign currencies, although the company presents its operating updates predominantly in US dollars.

Risks to Consider

Cogstate Limited (ASX:CGS) faces contract-concentration and timing risk because a limited number of late-stage studies can account for a significant proportion of quarterly sales. Trial cancellations, slower patient recruitment, protocol changes and sponsor decisions may defer work or affect the backlog. Expanding data-quality services also brings execution costs, technology investment, cybersecurity obligations and competition. A rising contract total does not ensure proportionate revenue growth in the same reporting period.

What to Watch Next

Investors following Cogstate Limited (ASX:CGS) can monitor subsequent FY27 quarterly contract updates, particularly the conversion of USD 56.8mn of FY27 contracted work into recognised revenue. Changes in licensing mix, Phase 3 delivery schedules and the USD 86.9mn of contracted revenue assigned to later years will also be relevant. Half-year financial results should clarify how trial activity affects margins, profit and cash receipts, as well as how technology spending develops.

Key Insights

Cogstate Limited (ASX:CGS) reported an increase in FY26 revenue and profit and subsequently added substantial contracts in the September 2026 quarter. The USD 143.7mn contracted revenue position provides visibility over assigned work but spans multiple years and remains exposed to trial timing. The principal near-term measures are contract execution, recognised revenue, operating costs and the conversion of longer-term trial awards into financial results.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.